Clinical Trials
12 trialsNCT02390752 2026-06-01
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT01254578 2017-09-25
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Phase 1 Completed
NCT00217646 2015-04-28
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00351975 2014-12-23
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Phase 1 Completed
NCT01132586 2014-12-23
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00301938 2013-09-30
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00331513 2013-09-30
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00357305 2013-05-03
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed
NCT00114257 2013-02-11
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005064 2013-01-23
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006213 2013-01-23
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00098826 2013-01-11
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed